AXGN · XBRL financial data

Axogen financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AXGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	112,300	127,358	138,584	159,012	187,338	225,208
Cost of goods and services sold	21,581	22,931	24,147	31,138	45,361	57,855
Gross profit	90,719	104,427	114,437	127,874	141,977	167,353
Research and development	17,846	24,177	27,158	28,333	27,767	32,885
General and administrative	26,396	32,338	36,758	34,943	39,036	44,577
Operating income (loss)	(23,182)	(25,416)	(29,707)	(21,462)	(3,287)	(7,849)
Interest expense	1,054	1,356	624	2,835	8,206	7,702
Other income (expense)	(38)	(278)	(230)	(437)	(199)	167
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(23,786)	(26,985)	(28,948)	(21,716)	(9,964)	(15,703)
Earnings per share, basic USD per share	(0.60)	(0.65)	(0.69)	(0.51)	(0.23)	(0.34)
Earnings per share, diluted USD per share	(0.60)	(0.65)	(0.69)	(0.51)	(0.23)	(0.34)
Weighted average shares, basic thousands of shares	39,967	41,215	42,083	42,879	44,258	46,050
Weighted average shares, diluted thousands of shares	39,967	41,215	42,083	42,879	44,258	46,050

Fiscal years (AXGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	48,767	32,756	15,284	31,024	27,554	35,548
Short-term investments	55,199	51,330	33,505	0	5,928	5,980
Accounts receivable	17,618	18,158	22,186	25,147	24,105	26,169
Inventory	12,529	16,693	18,905	23,020	33,183	42,373
Prepaid and other current assets	4,296	1,861	1,944	2,811	2,447	6,352
Total current assets	145,251	127,049	98,075	88,004	99,217	120,422
Property and equipment, net	38,398	62,881	—	—	—	—
Right-of-use asset	15,614	15,193	14,369	15,562	14,265	12,732
Total assets	201,381	208,024	195,387	196,827	203,728	221,687
Accounts payable	4,597	5,923	8,964	11,774	8,008	2,888
Total current liabilities	22,831	24,293	23,753	30,430	30,610	23,556
Long-term debt	32,027	44,821	45,712	46,603	47,496	48,387
Lease liability, non-current	20,864	20,794	20,387	21,123	19,191	16,838
Total liabilities	78,232	95,474	94,388	101,162	99,821	92,840
Accumulated deficit	(203,647)	(230,632)	(259,580)	(281,296)	(291,260)	(306,963)
Total stockholders' equity	123,149	112,550	100,999	95,665	103,907	128,847
Total liabilities and equity	201,381	208,024	195,387	196,827	203,728	221,687
Common shares outstanding (cover page) thousands of shares	40,737	41,795	42,602	43,206	44,344	51,898

Fiscal years (AXGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(23,786)	(26,985)	(28,948)	(21,716)	(9,964)	(15,703)
Stock-based compensation	8,470	10,919	15,591	14,418	15,906	30,112
Depreciation and amortization	1,530	2,744	2,827	4,218	6,467	6,660
Net cash from operating activities	(9,626)	(13,405)	(16,066)	(5,716)	4,535	812
Purchases of property and equipment	21,905	27,811	20,078	13,872	3,101	3,745
Net cash from investing activities	(16,963)	(23,649)	(3,200)	19,253	(10,297)	(5,317)
Proceeds from issuing common stock	3,500	0	0	—	—	—
Proceeds from long-term debt	35,000	15,000	0	0	—	—
Repayments of long-term debt	0	—	—	—	—	—
Net cash from financing activities	40,474	20,452	1,794	1,954	2,290	10,499
Net change in cash	13,885	(16,602)	(17,472)	15,491	(3,472)	5,994

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Ceribell	41,989	29,341	(13,078)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Butterfly Network	122,301	32,598	(2,266)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Heartflow	34,362	64,082	(8,577)*	87.0M	19.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.